Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers V > Headlines for Valeant Pharmaceuticals International > News item |
Valeant Pharmaceuticals investor ValueAct buys 2.5 million shares
By Lisa Kerner
Charlotte, N.C., May 15 - Investors led by ValueAct Master Fund, LP bought 2,535,629 shares of Valeant Pharmaceuticals International between May 7 and May 14 priced from $18.88 to $19.86 each, according to a schedule 13D/A filed on Friday with the Securities and Exchange Commission.
The investors beneficially own 15,776,929 shares, or 19.4%, of the Costa Mesa, Calif., specialty pharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.